These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 872137)

  • 1. Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats.
    Ward JM; Grabin ME; LeRoy AF; Young DM
    Cancer Treat Rep; 1977; 61(3):375-9. PubMed ID: 872137
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats.
    Pera MF; Zook BC; Harder HC
    Cancer Res; 1979 Apr; 39(4):1269-78. PubMed ID: 421210
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of mannitol or furosemide diuresis on cis-dichlorodiammineplatinum(II) antitumor activity and toxicity to host-renewing cell populations in rats.
    Pera MF; Harder HC
    Cancer Res; 1979 Apr; 39(4):1279-86. PubMed ID: 421211
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of a forced diuresis on the distribution and excretion (via urine and bile) of 195mplatinum when given as 195mplatinum cis-dichlorodiammineplatinum(II).
    DeSimone PA; Yancey RS; Coupal JJ; Butts JD; Hoeschel JD
    Cancer Treat Rep; 1979 Jun; 63(6):951-60. PubMed ID: 466654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of renal failure in rats receiving cis-diamminedichloroplatinum(II) by administration of furosemide.
    Ward JM; Grabin ME; Berlin E; Young DM
    Cancer Res; 1977 Apr; 37(4):1238-40. PubMed ID: 844049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of the renal toxicity of cis-dichlorodiammineplatinum(II) by probenecid.
    Ross DA; Gale GR
    Cancer Treat Rep; 1979 May; 63(5):781-7. PubMed ID: 455315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Functional morphology of the kidney in diuresis and antidiuresis].
    Orlov VS
    Arkh Anat Gistol Embriol; 1974 May; 66(5):99-104. PubMed ID: 4618093
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing.
    Levi FA; Hrushesky WJ; Blomquist CH; Lakatua DJ; Haus E; Halberg F; Kennedy BJ
    Cancer Res; 1982 Mar; 42(3):950-5. PubMed ID: 7199382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal response to furosemide in normal subjects during hyperinsulinaemic clamp.
    Tedde R; Sechi LA; Melis A
    Boll Soc Ital Biol Sper; 1990 Jul; 66(7):685-92. PubMed ID: 2083062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic cisplatin nephropathy in rats.
    Choie DD; Longnecker DS; del Campo AA
    Lab Invest; 1981 May; 44(5):397-402. PubMed ID: 7194946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity.
    Hanigan MH; Gallagher BC; Taylor PT; Large MK
    Cancer Res; 1994 Nov; 54(22):5925-9. PubMed ID: 7954424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects and interactions of furosemide and acetazolamide on tubular function in rat kidney.
    Rodicio JL; Hernando L
    Rev Esp Fisiol; 1977 Jun; 33(2):113-8. PubMed ID: 877378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological blockade of the nephrotoxicity of cisplatin in rats].
    Natochin IuV; Raznik LV; Bakhteeva VT; Ivanov VB; Miazina EM
    Biull Eksp Biol Med; 1986 Oct; 102(10):442-5. PubMed ID: 3768510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin urinary pharmacokinetics and nephrotoxicity: a common circadian mechanism.
    Levi F; Hrushesky WJ; Borch RF; Pleasants ME; Kennedy BJ; Halberg F
    Cancer Treat Rep; 1982 Nov; 66(11):1933-8. PubMed ID: 6890406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithium clearance as an indicator of proximal tubular sodium handling during furosemide diuresis.
    Christensen S; Shalmi M; Petersen JS
    J Pharmacol Exp Ther; 1988 Aug; 246(2):753-7. PubMed ID: 3404456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose dependence of proximal and distal tubular effects of furosemide in conscious rats.
    Christensen S; Petersen JS; Steiness E; Andreasen F
    J Pharmacol Exp Ther; 1987 Jun; 241(3):987-93. PubMed ID: 3598915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. cis-Dichlorodiammineplatinum nephrotoxicity in rats of different ages.
    Braunlich H; Kuo CH; Slocombe R; Hook JB
    Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):279-91. PubMed ID: 6539942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplacental carcinogenesis by cisplatin in F344/NCr rats: promotion of kidney tumors by postnatal administration of sodium barbital.
    Diwan BA; Anderson LM; Ward JM; Henneman JR; Rice JM
    Toxicol Appl Pharmacol; 1995 May; 132(1):115-21. PubMed ID: 7747274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
    Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
    Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.
    Osman NM; Copley MP; Litterst CL
    Cancer Treat Rep; 1984; 68(7-8):999-1004. PubMed ID: 6540145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.